Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

Hims & Hers stock: why today's gains are unlikely to be sustainable

But Hims & Hers shares are unlikely to sustain these gains over time. The stock is still down some 38% versus its ...

What’s Happening With HIMS Stock?

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a ...

Hims expansion may not come in time for risky GLP-1 business

By Amina Niasse NEW YORK, March 2 (Reuters) - Telehealth company Hims & Hers Health, known for its weight-loss drug business, ...

Hims & Hers Short Squeeze Is Looking Dangerous (Rating Downgrade)

Hims & Hers is downgraded to hold as the 40% rally after Novo Nordisk’s dismissal of its lawsuit is likely driven by a short ...

Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warning

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug ...